GSTM1 and anemia: In this single-arm, prospective, longitudinal, multicenter observational study, approximately 80% of patients with symptomatic chemotherapy-induced anemia had a Hb in the range of 9–11 g/dL prior to antianemic treatment with darbepoetin alfa.